LEO Pharma appoints Chris Posner to lead US business

Danish drugmaker LEO Pharma today announced that it appointed Chris Posner as executive vice president Region US and president and chief executive LEO Pharma Inc. From July 15, 2017, he will be responsible for the US business of LEO Pharma, a global healthcare company dedicated to helping people achieve healthy skin.

"Chris Posner brings extensive experience in the US market including biologic medicines and immunology. LEO Pharma is expanding in the United States, both in topical treatments for psoriasis and actinic keratosis and in systemic treatments for dermatologic conditions," said Gitte Aabo, president and CEO of LEO Pharma, adding: "We are committed to strengthen our presence in the United States, organically as well as through potential acquisitions. Chris Posner is the right person to accelerate our presence and enable us to help people achieve healthy skin in the United States."

Chris Posner joins LEO Pharma from R-Pharm US, a unit of Russia’s R-Pharm CJSC and a specialty pharmaceutical start-up focused on oncology and chronic immune diseases, where he has been head of worldwide commercial operations. He has wide-ranging experience in the pharma industry including biologic medicines and immunology from leading the commercialization of US and global brands at Bristol-Myers-Squibb, Pfizer, Wyeth, Endo and Merck & Co.